Press release
Axial Spondyloarthritis (axSpA) Market was valued at ~USD 6.3 billion in 2024 and is projected to reach ~USD 11.8 billion by 2034
Axial Spondyloarthritis (axSpA) Market
The Axial Spondyloarthritis (axSpA) market was valued at ~USD 6.3 billion in 2024 and is projected to reach ~USD 11.8 billion by 2034, registering a CAGR of around 6.7%. Rising diagnosis of non-radiographic axSpA, increased awareness among rheumatologists, and rapid adoption of biologics are the main factors driving growth.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71307
Key Market Drivers
• Growing recognition of non-radiographic axSpA as a distinct and treatable condition.
• Increased use of TNF inhibitors and IL-17 inhibitors as first-line biologics.
• Development of advanced MRI techniques enabling earlier detection.
• Expansion of rheumatology clinics and improved access to specialty care.
Challenges
• High cost of biologics limits adoption in emerging markets.
• Underdiagnosis due to symptom overlap with chronic back pain.
• Long treatment duration increases economic burden on patients and payers.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/71307/axial-spondyloarthritis-market
Market Segmentation
By Drug Class
• TNF inhibitors
• IL-17 inhibitors
• JAK inhibitors
• NSAIDs & conventional therapies
By Disease Type
• Radiographic axSpA (Ankylosing Spondylitis)
• Non-radiographic axSpA
By End User
• Hospitals
• Specialty rheumatology clinics
• Homecare / self-administration
By Distribution Channel
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies
Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71307
Regional Snapshot
• North America dominates due to strong biologic penetration and early diagnosis.
• Europe shows steady growth supported by reimbursement and clinical guidelines.
• Asia-Pacific is the fastest-growing market due to rising patient awareness and expanding specialist care access.
Key Companies
AbbVie, Novartis, UCB, Eli Lilly, Amgen, Pfizer, Johnson & Johnson, Bristol Myers Squibb.
Future Outlook
Growth will be driven by new IL-17 and JAK inhibitors, improved early detection, and increasing adoption of home-based self-injectable therapies. Expansion in emerging markets and biosimilar penetration will further strengthen market growth.
This report is also available in the following languages : Japanese (軸性脊椎関節炎市場), Korean (축성 척추관절염 시장), Chinese (轴性脊柱关节炎市场), French (Marché de la spondylarthrite axiale), German (Markt für axiale Spondyloarthritis), and Italian (Mercato della spondiloartrite assiale), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71307
Our More Reports:
Atypical Hemolytic Uremic Syndrome Market
https://exactitudeconsultancy.com/reports/71273/atypical-hemolytic-uremic-syndrome-market
Chronic Venous Insufficiency Market
https://exactitudeconsultancy.com/reports/71275/chronic-venous-insufficiency-market
Diamond Blackfan Anemia Market
https://exactitudeconsultancy.com/reports/71277/diamond-blackfan-anemia-market
Fanconi Anemia Market
https://exactitudeconsultancy.com/reports/71277/diamond-blackfan-anemia-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Axial Spondyloarthritis (axSpA) Market was valued at ~USD 6.3 billion in 2024 and is projected to reach ~USD 11.8 billion by 2034 here
News-ID: 4310937 • Views: …
More Releases from Exactitude Consultancy
Adult-onset Still Disease (AOSD) market growing at a CAGR of around 7.7%
The Adult-onset Still Disease (AOSD) market was valued at ~USD 1.2 billion in 2024 and is projected to reach ~USD 2.5 billion by 2034, growing at a CAGR of around 7.7%. Rising diagnosis rates, improved biomarker-based testing, and strong adoption of biologics are the primary growth drivers.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71305
Key Market Drivers
• Increasing awareness and improved identification of AOSD cases.
• Growing use of IL-1 and IL-6 inhibitors…
Medullary Thyroid Cancer (MTC) Market is projected to reach USD 1.19 billion by …
The global Medullary Thyroid Cancer (MTC) Market was valued at USD 672 million in 2024 and is projected to reach USD 1.19 billion by 2034, growing at a CAGR of 5.8% from 2025 to 2034. Market growth is driven by increasing adoption of targeted therapies, improved genetic testing for RET mutations, rising incidence of thyroid cancers globally, and advancements in minimally invasive diagnostic and surgical techniques.
Download Full PDF Sample Copy…
Disseminated Intravascular Coagulation (DIC) Market was valued at USD 1.42 billi …
The Disseminated Intravascular Coagulation (DIC) Market is expanding as the global incidence of sepsis, trauma cases, obstetric complications, and malignancy-related coagulation disorders continues to rise. DIC is a serious, life-threatening hematological condition characterized by systemic activation of the coagulation cascade, leading to organ failure, hemorrhage, and microvascular thrombosis.
Demand for rapid diagnostics, advanced coagulation testing, and critical-care therapies has increased significantly in recent years.
The global DIC market was valued at USD…
Malignant Glioma Market is projected to reach USD 8.03 billion by 2034
The global Malignant Glioma Market was valued at USD 4.62 billion in 2024 and is projected to reach USD 8.03 billion by 2034, growing at a CAGR of 5.7% from 2025 to 2034. Market growth is fueled by increasing incidence of high-grade gliomas, rising adoption of targeted and immunotherapy approaches, continued innovation in brain tumor imaging and surgical technologies, and growing investment in precision oncology for central nervous system (CNS)…
More Releases for Spondyloarthritis
Axial Spondyloarthritis Market Dynamics Indicate Upward Trajectory Through 2034, …
DelveInsight's "Axial Spondyloarthritis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Axial Spondyloarthritis, historical and forecasted epidemiology as well as the Axial Spondyloarthritis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Axial Spondyloarthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Axial Spondyloarthritis Market Forecast
https://www.delveinsight.com/sample-request/axial-spondyloarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Axial Spondyloarthritis Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Axial Spondyloarthritis Pipeline Insight 2024" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Axial Spondyloarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Axial Spondyloarthritis Research. Learn more about…
Axial Spondyloarthritis (axSpA) Industry - Key Market Dynamics and Trends
The axial spondyloarthritis (axspa) market size has grown strongly in recent years. It will grow from $5.54 billion in 2023 to $6.04 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to improved diagnostic criteria, biological treatment advancements, rising disease awareness, genetic research advances, clinical trial progress.
The axial spondyloarthritis (axspa) market size is expected to see…
Axial Spondyloarthritis Drug Market to see Rapid Growth by 2029
The global axial spondyloarthritis drug market is anticipated to grow at a considerable CAGR of 4.1% during the forecast period. The market is primarily driven by favourable conditions for pharmaceutical producers and the attention of various government agencies on enhancing the current healthcare infrastructure. These will lead to a rise in global demand for various drugs for treatment options for axial spondyloarthritis in the near future. Additionally, significant investment in research and…
Optimization Of Workflows To Catalyse The Axial Spondyloarthritis Treatment Mark …
Axial spondyloarthritis is a type of inflammatory arthritis which primarily affects the axial skeleton such as pelvic joints and spine. Generally ankylosing spondylitis (AS), an inflammatory disease of the sacroiliac joints and spine are collectively termed as axial spondyloarthritis.
The axial spondyloarthritis is divided in two stages namely non- radiographic and radiographic stage. Severe and chronic back pain is the major symptom of this complication along with buttock pain and pain…
Axial Spondyloarthritis Global Clinical Trials Review, H1, 2017
"The Report Axial Spondyloarthritis Global Clinical Trials Review, H1, 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
About Axial Spondyloarthritis Market
Summary
GlobalData's clinical trial report, Axial Spondyloarthritis Global Clinical Trials Review, H1, 2017" provides an overview of Axial Spondyloarthritis clinical trials scenario. This report provides top line data relating to the clinical trials on Axial Spondyloarthritis. Report includes an overview of trial…
